Karl Storz announced today that it acquired the medical business of T1V, a visual collaboration software company. According to a news release, Karl Storz already has a longstanding partnership with T1V to build its existing CollaboratOR portfolio. The company says its acquisition “marks a significant step” toward shaping integrated hardware and software for digital surgery. […]
Mergers & Acquisitions
Boston Scientific makes IVL play with Bolt Medical acquisition
Boston Scientific announced today that it agreed to acquire intravascular lithotripsy (IVL) platform developer Bolt Medical. On a 100% basis — before considering an existing equity stake and other adjustments — the deal is valued at $600 million upfront with up to an additional $300 million upon achievement of certain regulatory milestones. The acquisition marks […]
Stryker strikes $4.9B deal to buy Inari Medical
Stryker today said it has a definitive agreement to purchase Inari Medical for $80 per share, a big premium that puts the deal’s value at $4.9 billion. Shares of Inari Medical were trading around $48 earlier today. The deal was announced after market close. The deal has been approved by the boards of both Portage, […]
Hologic completes acquisition of Gynesonics
Hologic announced today that it completed its $350 million acquisition of Gynesonics. Marlborough, Massachusetts–based Hologic announced an agreement to buy Gynesonics in October. Gynesonics develops minimally invasive medical device solutions for women’s health, including the Sonata system. Gynesonics designed Sonata for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids. That includes those […]
Bioventus divests Advanced Rehabilitation business to PE firm
Bioventus (Nasdaq:BVS) announced today that it successfully completed the divestiture of its Advanced Rehabilitation business. The Durham, North Carolina-based company divested the unit to Accelmed Partners. Accelmed, a private equity (PE) firm, focuses on acquiring and growing commercial-stage healthtech companies. Bioventus initially announced the deal to divest Advanced Rehabilitation on Oct. 1, 2024. The company […]
The top medtech stories of 2024
AFib-treating cardiac ablation, surgical robotics, nitinol and diabetes treatment tech lead among this year’s top medtech stories. Meanwhile, medical device companies have been seeking more tuck-in M&A — and continuing to refocus and boost operational efficiency — to better prepare for whatever the future brings. Here are the top medtech stories that caught the attention […]
The biggest medtech M&A moves of 2024
In 2024, we saw another proactive year for some of the biggest names in medtech as they looked to bolster their ranks through acquisitions. Over the course of the year, the number of billion-dollar sales deals continued to climb, with some companies involved more than once. Analysts even suggested that, in 2025, there could be […]
Electrocore to acquire NeuroMetrix and its Quell neuromod tech
ElectroCore (Nasdaq:ECOR) announced that it agreed to acquire NeuroMetrix (Nasdaq:NURO) and its Quell neuromodulation platform. NeuroMetrix develops the Quell platform, a wearable, app- and cloud-enabled neuromodulation platform. It treats fibromyalgia symptoms and lower-extremity chronic pain. The company also offers DPNCheck, a point-of-care screening test for peripheral neuropathy. However, ElectroCore said it expects NeuroMetrix to divest […]
Teleflex reportedly in talks to buy Biotronik stent business
Teleflex could agree as soon as this month to acquire Biotronik’s vascular intervention unit. That’s according to a Dec. 4 Bloomberg report that cited people familiar with the matter, who said Teleflex was offering €500 million to €1 billion for the stent business. In a report out today, Needham & Co. Senior Research Analyst Mike […]
Bausch + Lomb is exploring a potential sale
Bausch + Lomb announced today that, in response to a request from regulatory authorities, it authorized the exploration of a potential sale. The Vaughan, Ontario-based eye care company received a request from the Canadian Investment Regulatory Organization (CIRO). It was related to stock volatility and market rumors. Bausch + Lomb stock trades on the New […]
Bausch + Lomb acquires glaucoma treatment company Elios Vision
Bausch + Lomb announced today that an affiliate acquired Elios Vision, developer of a minimally invasive glaucoma surgery (MIGS) procedure. The Elios procedure uses an excimer laser to treat glaucoma in conjunction with cataract surgery without implants. Bausch + Lomb believes the deal enhances its glaucoma portfolio which already features pharmaceutical and surgical approaches. Compared […]
